Lysergic acid diethylamide : a drug of ‘use’ ? Saibal Das, Preeti Barnwal, Anand Ramasamy, Sumalya Sen and Somnath Mondal Therapeutic Advances in Psychopharmacology, 2016, Vol. 6, (3), 214–228 DOI: 10.1177/2045125316640440 Abstract : Lysergic acid diethylamide (LSD), described as a classical hallucinogen, began its journey from the middle of the last century following an accidental discovery. Since then, it was used as a popular and notorious substance of abuse in various parts of the world. Its beneficial role as an adjunct to psychotherapy was much unknown, until some ‘benevolent’ experiments were carried out over time to explore some of its potential uses. But, many [...]
Lire la suitePrevalence and Correlates of Cannabis Use in Outpatients with Serious Mental Illness Receiving Treatment for Alcohol Use Disorders Jordan Skalisky, Emily Leickly, Oladunni Oluwoye, Sterling M. McPherson, Debra Srebnik, John M. Roll, Richard K. Ries, and Michael G. McDonell Cannabis and Cannabinoid Research, 2017, 2, (1), 133-138 DOI: 10.1089/can.2017.0006 Abstract Introduction : People with serious mental illness (SMI) use cannabis more than any other illicit drug. Cannabis use is associated with increased psychotic symptoms and is highly comorbid with alcohol use disorders (AUDs). Despite the national trend toward decriminalization, little is known about the prevalence, correlates, and impact of cannabis use on those with SMI [...]
Lire la suiteCannabidiol Does Not Dampen Responses to Emotional Stimuli in Healthy Adults David L. Arndt and Harriet de Wit Cannabis and Cannabinoid Research, 2017, 2, (1), 105-113 DOI: 10.1089/can.2017.0014 Abstract Introduction : Cannabidiol (CBD) is a nonpsychoactive constituent of whole plant cannabis that has been reported to reduce anxiety-like behaviors in both pre-clinical and human laboratory studies. Yet, no controlled clinical studies have demonstrated its ability to reduce negative mood or dampen responses to negative emotional stimuli in humans. The objective of this study was to investigate the effects of CBD on responses to negative emotional stimuli, as a model for its potential anxiety-reducing effects. Materials and [...]
Lire la suiteThe Neurobiology of Psychedelic Drugs: Implications for the Treatment of Mood Disorders Franz X. VOLLENWEIDER & Michael KOMETER Nature Reviews Neuroscience, 2010, 11, (9), 642-51 DOI: 10.1038/nrn2884 Abstract After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical [...]
Lire la suiteLegally high ? Legal considerations of Salvia divinorum O. Hayden GRIFFIN III, Bryan Lee MILLER, David N. KHEYS Journal of Psychoactive Drugs, 2008, 40, (2), 183-190 In the past few years, there has been an apparent increase in the recreational use of Salvia divinorum. Its origins lie in the Mazatecan culture where its ceremonial use had historic ties to the traditional mystic religion and medicine practiced by its people. This psychoactive plant is native to the forest ravines of Oaxaca, Mexico--the area inhabited by the Mazatecs. It is a relative in the mint family, a family of plants that includes several psychoactive species. [...]
Lire la suiteChanvre industriel, bien-être, cannabis médical, récréatif : pourquoi ces distinctions ? Aurélien Bernard NEWSWEED, Cannabis en France 18 juillet 2019 Une question nous est revenue à plusieurs reprises suite au récapitulatif du colloque sur le chanvre bien-être : pourquoi parler de « chanvre bien-être » ? Si l’on peut effectivement s’interroger sur la nécessité d’avoir toutes ces dénominations, elles servent pourtant à dissocier à la fois les usages et l’aspect réglementaire franco-français du cannabis. Nous avons donc : du chanvre industriel : variétés de cannabis à -0,2% de THC, pour un usage fibres et graines du chanvre bien-être : variétés de cannabis à -0,2% de [...]
Lire la suiteCannabis à visée thérapeutique en France : l’ANSM souscrit au cadre de la phase expérimentale de mise à disposition proposé par le Comité d’experts - Point d'information 11/07/2019 L’Agence nationale de sécurité du médicament et des produits de santé (ANSM) souscrit aux propositions du groupe d’experts (CSST) publiées le 28 juin sur le cadre pratique de l’accès au cannabis à visée thérapeutique en vue d’une expérimentation en France. L’agence et le ministère des solidarités et de la santé engagent dès à présent les travaux nécessaires à la mise en place de l’expérimentation.Le comité d’experts mis en place par l’ANSM en septembre 2018 [...]
Lire la suitePsychedelics and Mental Health : A Population Study Teri S. Krebs, Pal-Ørjan Johansen PLoS ONE, 2013, 8, (8): e63972. doi:10.1371/journal.pone.0063972 Abstract Background : The classical serotonergic psychedelics LSD, psilocybin, mescaline are not known to cause brain damage and are regarded as non-addictive. Clinical studies do not suggest that psychedelics cause long-term mental health problems. Psychedelics have been used in the Americas for thousands of years. Over 30 million people currently living in the US have used LSD, psilocybin, or mescaline. Objective : To evaluate the association between the lifetime use of psychedelics and current mental health in the adult population. Method : Data drawn from years 2001 [...]
Lire la suitePrehistoric peyote use : Alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas Hesham R. El-Seedi, Peter A.G.M. De Smet, Olof Beck, G¨oran Possnert, Jan G. Bruhn Journal of Ethnopharmacology, 2005, 101, 238–242 doi:10.1016/j.jep.2005.04.022 Abstract Two archaeological specimens of peyote buttons, i.e. dried tops of the cactus Lophophora williamsii (Lem.) Coulter, from the collection of theWitte Museum in San Antonio, was subjected to radiocarbon dating and alkaloid analysis. The samples were presumably found in Shumla Cave No. 5 on the Rio Grande, Texas. Radiocarbon dating shows that the calibrated 14C age of the weighted mean of the two individual dated samples corresponds to [...]
Lire la suitePotential Psychiatric Uses for MDMA B.B. Yazar-Klosinski and M.C. Mithoefer CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101, 2 www.wileyonlinelibrary/cpt doi:10.1002/cpt.565 Phase II trials of 3,4-methylenedioxymethamphetamine (MDMA)- assisted psychotherapy have demonstrated initial safety and efficacy for treatment of posttraumatic stress disorder (PTSD), with potential for expansion to depression and anxiety disorders. In these trials, single doses of MDMA are administered in a model of medication-assisted psychotherapy, differing from trials involving daily drug administration without psychotherapy. This model presents an opportunity to utilize accelerated regulatory pathways, such as the US Food and Drug Administration (FDA) Breakthrough Therapy Designation, to most effectively and expeditiously test such novel approaches. BACKGROUND MDMA-assisted [...]
Lire la suite